Does Adjuvant Mitotane Impact Cure Rates in Adrenocortical Carcinoma? Insights From the ICARO-GETTHI/SEEN Registry
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgaf082 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Alberto Carmona-Bayonas und 23 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Hospital Universitario Morales Meseguer, Instituto Murciano de Investigación Biosanitaria (IMIB), Universidad de Murcia …. Hauptthemen laut MEDLINE: Mitotane, Adrenocortical Carcinoma, Adrenal Cortex Neoplasms, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Grupo Español Medicina Traslacional y Tumores Huérfanos e Infrecuentes, Sociedad Española de Endocrinología y Nutrición, Esteve-HRA Pharm Rare Disease.
Abstract (Originalsprache)
Context
Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy with a high risk of postoperative recurrence. Although adjuvant mitotane is commonly used, its potential for achieving cure rather than simply postponing inevitable recurrence remains uncertain.
Objective
This study investigates whether mitotane impacts ACC recurrence patterns by preventing or delaying recurrence.
Methods
This retrospective analysis used data from the ICARO-GETTHI/SEEN registry, which includes 36 Spanish hospitals. Recurrence in nonmetastatic ACC patients after resection was analyzed using Cox models, flexible longitudinal models, and mixture cure models to evaluate the impact of mitotane.
Results
Among 244 patients, 133 (52%) received adjuvant mitotane, with therapeutic levels monitored in 84%. Findings suggest a possible “cure fraction” with a 32.5% estimated 30-year cure rate (95% CI, 23.4%-45.0%). Cox regression indicated a 39% reduced recurrence risk (HR 0.61; 95% CI, 0.39-0.95) for mitotane-treated patients, with effects diminishing over 24 months. Mixture cure models suggest mitotane primarily delays rather than prevents recurrence. Effect modification analysis showed significant benefit in male patients (HR 0.33; 95% CI, 0.16-0.69), younger patients, tumors with higher Ki-67% (modeled as a continuous variable), and those with venous invasion (HR 0.47; 95% CI, 0.27-0.82), with potential synergy when combined with radiotherapy.
Conclusion
This study underscores the intriguing possibility that adjuvant mitotane delays recurrence, yet questions remain as to its curative capacity. The early benefit suggests a cytostatic effect, but certain subgroups—especially males, younger individuals, and those with high-risk tumors—may experience a more durable outcome. Further research is needed to explore mitotane's curative potential in ACC management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology Department, Hospital Universitario Morales Meseguer, Instituto Murciano de Investigación Biosanitaria (IMIB), Universidad de Murcia (UMU), 30008 Murcia, Spain.
- Endocrinology and Nutrition Department, Hospital Universitario La Paz, 28046 Madrid, Spain.
- Medical Oncology Department, Hospital Universitario Morales Meseguer, 30008 Murcia, Spain.
- Gastrointestinal and Endocrine Tumors Unit, Medical Oncology Department, Hospital Universitario Val de Hebrón, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
- Endocrinology and Nutrition Department, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain.
- Endocrinology and Nutrition Department, Hospital General Universitario Gregorio Marañon, 28007 Madrid, Spain.
ORCID-Profile: Alberto Carmona-Bayonas, Cristina Álvarez-Escolá, Jorge Hernando Cubero, Miguel Ángel Mangas Cruz, Rogelio Garcia-Centeno, Clara Iglesias, Jesús García-Donas, María José Picón, Lorena González Batanero, Lourdes García, Teresa Alonso Gordoa, Carlos López, Felicia Hanzu, Javier Martínez-Trufero, Beatriz Febrero, Patricia Saiz-López, Concepción Blanco Carrera, Teresa Ramón Y Cajal, Oswaldo Gressani, Nuria Valdés, Paula Jimenez-Fonseca
Förderung
- Grupo Español Medicina Traslacional y Tumores Huérfanos e Infrecuentes
- Sociedad Española de Endocrinología y Nutrición
- Esteve-HRA Pharm Rare Disease
Zitieren
APA
Carmona-Bayonas, A., Álvarez-Escolá, C., Ballester Navarro, I., Hernando Cubero, J., Mangas Cruz, M. Á., Garcia-Centeno, R., Iglesias, C., García-Donas, J., Picón, M. J., Paja, M., González Batanero, L., García, L., Alonso Gordoa, T., López, C., Hanzu, F., Martínez-Trufero, J., Febrero, B., Saiz-López, P., Blanco Carrera, C., …, & Jimenez-Fonseca, P. (2025). Does Adjuvant Mitotane Impact Cure Rates in Adrenocortical Carcinoma? Insights From the ICARO-GETTHI/SEEN Registry. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf082
Vancouver
Carmona-Bayonas A, Álvarez-Escolá C, Ballester Navarro I, Hernando Cubero J, Mangas Cruz MÁ, Garcia-Centeno R, et al. Does Adjuvant Mitotane Impact Cure Rates in Adrenocortical Carcinoma? Insights From the ICARO-GETTHI/SEEN Registry. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf082
BibTeX
@article{CarmonaBayonas2025,
author = {Carmona-Bayonas, Alberto and Álvarez-Escolá, Cristina and Ballester Navarro, Inmaculada and Hernando Cubero, Jorge and Mangas Cruz, Miguel Ángel and Garcia-Centeno, Rogelio and Iglesias, Clara and García-Donas, Jesús and Picón, María José and Paja, Miguel and González Batanero, Lorena and García, Lourdes and Alonso Gordoa, Teresa and López, Carlos and Hanzu, Felicia and Martínez-Trufero, Javier and Febrero, Beatriz and Saiz-López, Patricia and Blanco Carrera, Concepción and Ramón Y Cajal, Teresa and Veiguela, Brenda and Gressani, Oswaldo and Valdés, Nuria and Jimenez-Fonseca, Paula},
title = {Does Adjuvant Mitotane Impact Cure Rates in Adrenocortical Carcinoma? Insights From the ICARO-GETTHI/SEEN Registry},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgaf082}
}
EUVIMED